Literature DB >> 9854687

Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases.

S Grosso1, R Berardi, M Cioni, G Morgese.   

Abstract

Amiodarone (AMD) is an antiarrhythmic drug which contains 37% of iodine. It can reach the fetus by transplacental passage and induce fetal hypothyroidism. Since in some pregnant women AMD represents a cardinal therapeutic opportunity, it is necessary to establish not only the risk of teratogenicity linked to fetal AMD exposure but also to evaluate the psychomotor development of children with neonatal thyroid dysfunction related to fetal AMD exposure. We report on two cases involving children with an AMD gestational exposure and transient neonatal hypothyroidism, who were followed-up until the age of 4 years 8 months and 5 years 6 months, respectively. Denver's developmental milestone test and Whechsler Preschool and Primary Scale of Intelligence (WPPSI) were administered to the patients in accordance to their age. A normal psychomotor development was observed in both patients with full scale IQ score, verbal and performance IQ scores within normal range. In conclusion, if these data were validated by larger studies, it might not be obligatory to discontinue AMD administration in cardiopathic pregnant women, since mental impairment may not necessarily occur in children with transient neonatal hypothyroidism caused by fetal AMD exposure. However, the evaluation of the thyroid function of these children is imperative.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854687     DOI: 10.1007/BF03350801

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

Review 1.  Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy.

Authors:  J Widerhorn; A K Bhandari; S Bughi; S H Rahimtoola; U Elkayam
Journal:  Am Heart J       Date:  1991-10       Impact factor: 4.749

2.  Neurodevelopment in infants and preschool children with congenital hypothyroidism: etiological and treatment factors affecting outcome.

Authors:  J F Rovet; R M Ehrlich; D L Sorbara
Journal:  J Pediatr Psychol       Date:  1992-04

3.  Effects of amiodarone during pregnancy.

Authors:  E Rey; L K Bachrach; G N Burrow
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

4.  Fetal hypothyroidism as a complication of amiodarone treatment for persistent fetal supraventricular tachycardia.

Authors:  L De Catte; D De Wolf; J Smitz; A Bougatef; J De Schepper; W Foulon
Journal:  Prenat Diagn       Date:  1994-08       Impact factor: 3.050

5.  The Denver developmental screening test.

Authors:  W K Frankenburg; J B Dodds
Journal:  J Pediatr       Date:  1967-08       Impact factor: 4.406

6.  Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  M D Trip; W Wiersinga; T A Plomp
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

7.  Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease.

Authors:  E Martino; F Aghini-Lombardi; L Bartalena; L Grasso; A Loviselli; F Velluzzi; A Pinchera; L E Braverman
Journal:  Arch Intern Med       Date:  1994 Dec 12-26

Review 8.  Pharmacology and pharmacokinetics of amiodarone.

Authors:  M D Freedman; J C Somberg
Journal:  J Clin Pharmacol       Date:  1991-11       Impact factor: 3.126

Review 9.  [Effects of amiodarone on thyroid function].

Authors:  P Caron
Journal:  Presse Med       Date:  1995-12-02       Impact factor: 1.228

10.  Pregnancy outcome after gestational exposure to amiodarone in Canada.

Authors:  L A Magee; E Downar; M Sermer; B C Boulton; L C Allen; G Koren
Journal:  Am J Obstet Gynecol       Date:  1995-04       Impact factor: 8.661

View more
  1 in total

Review 1.  Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.

Authors:  L Bartalena; F Bogazzi; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.